Here are the names.
Samsung's Bioepis unit seeks final approval in Europe of a rheumatoid arthritis drug to compete with Humira.
Investors should watch these companies come July 18th.
Down-and-out stocks have become toxic.
©1996-2017 TheStreet, Inc. All rights reserved.
Action Alerts PLUS is a registered trademark of TheStreet, Inc.